Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierSTAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction.
In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR
Business segments
Q2 2026 · $44.7MThe company’s own SEC segment disclosure.
- Other Countries$19.7M44%
- Japan$11.1M25%
- China$9.5M21%
- South Korea$4.3M10%
STAAR Surgical Company (STAA) reported revenue of $94M in Q1 2026 (quarter ended April 3, 2026), up 120% from the same quarter a year earlier. That came with a gross margin of 74% and net income of $5.2M (5.6% of revenue). For the full year FY2025, revenue was $239M (−24% year on year) and net income −$80M. Its largest region in 2026-Q2 was Other Countries at $20M, 44% of the disclosed total, just ahead of Japan at 25%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #1 of 27 by Smart Score